Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Omalizumab is effective and well-tolerated in children with moderate to severe allergic asthma. However, the effects of long-term treatment with omalizumab in this population haven't been well investigated. The objective of this study is to evaluate the long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with uncontrolled severe asthma.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Allergol Int

Title: Allergology international : official journal of the Japanese Society of Allergology

Publisher: Elsevier BV

ISSN (Electronic): 1440-1592

ISSN (Print): 1323-8930

Publication date (Electronic): Jan 2017

Volume: 66

Issue: 1

Affiliations

[1 ] Department of Pediatrics, Fukuoka National Hospital, Fukuoka, Japan. Electronic address: odaji@mfukuoka2.hosp.go.jp.

[2 ] Department of Allergy, Clinical Research Center for Allergology and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.

[3 ] Yoga Allergy Clinic, Tokyo, Japan.

[4 ] Institute for Clinical Research, Mie National Hospital, Tsu, Japan.

[5 ] Division of Allergy, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

[6 ] Department of Allergy, Aichi Children's Health and Medical Center, Obu, Japan.

[7 ] Department of Pediatrics, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Japan.

[8 ] Department of Pediatrics, The Fraternity Memorial Hospital, Tokyo, Japan.

[9 ] Department of Pediatrics, Jikei Daisan Hospital, Tokyo, Japan.

[10 ] Department of Allergy, Kanagawa Children's Medical Center, Yokohama, Japan.

[11 ] Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.

[12 ] Department of Pediatrics, Fukuyama Medical Center, Fukuyama, Japan.

[13 ] Department of Pediatrics, Tenri Hospital, Tenri, Japan.

[14 ] Department of Allergy and Rheumatology, Chiba Children's Hospital, Chiba, Japan.

[15 ] Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.

[16 ] Clinical Development, Novartis Pharma K.K., Tokyo, Japan.

[17 ] Department of Pediatrics, Fukuoka National Hospital, Fukuoka, Japan.

Article

Publisher Item ID: S1323-8930(16)30088-0

DOI: 10.1016/j.alit.2016.06.004

PubMed ID: 27507228

SO-VID: 44a5e064-6d4b-4def-b5ae-a8fef08fd94c

History

Keywords: Childhood asthma,Efficacy,Omalizumab,Safety evaluation,Total IgE

Data availability:

Keywords: Childhood asthma, Efficacy, Omalizumab, Safety evaluation, Total IgE

Comments

Comment on this article

scite_

Cited by 15

See all cited by

- Version 1